Recent Updates
Recently added Catalysts
COAG Positive Sentiment

Hemab Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update

Tuesday, August 11, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Hemab Therapeutics reported its second quarter 2026 financial results, highlighting key scientific presentations at the ISTH 2026 Congress in Paris. The company showcased new clinical data for HMB-002, which demonstrated a notable 2.4-fold increase in Von Willebrand Factor (VWF). This progress reflects Hemab's commitment to advancing its therapeutic programs.

Market Sentiment Analysis

POSITIVE FACTORS

  • Significant clinical data presented at ISTH 2026 Congress.
  • HMB-002 showed a 2.4-fold increase in Von Willebrand Factor.
  • Multiple oral presentations highlight the company's research progress.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+109%
120-day peak, hindsight
Typical move
13.9%
average across 3 past catalysts
Cash runway
~20 mo
Low dilution risk
Lead asset
Sutacimig
Phase 2 · Congenital Factor VII Deficiency

Full Press Release Details

Multiple scientific data presentations, including five oral presentations across three programs, at the International Society on Thrombosis and Haemostasis (ISTH) 2026 Congress in Paris, France New clinical data on HMB-002 demonstrated 2.4-fold increase in Von Willebrand Factor (VWF) and Factor

Frequently Asked Questions

What were the highlights of Hemab's Q2 2026 report?

Hemab reported significant clinical data presentations and a 2.4-fold increase in Von Willebrand Factor from HMB-002.

Where were the data presentations held?

The presentations took place at the International Society on Thrombosis and Haemostasis (ISTH) 2026 Congress in Paris.

What is HMB-002?

HMB-002 is a therapeutic program by Hemab Therapeutics that showed promising clinical results.

How many oral presentations did Hemab have at ISTH 2026?

Hemab had five oral presentations across three programs at the ISTH 2026 Congress.

ShareAdd on Google
Tags: COAG Viatris Investor Conferences Healthcare Hemab Therapeutics HMB-002 ISTH 2026 Von Willebrand Factor clinical data
Last updated: Aug 11, 2026

Biotech snapshot

Cash runway
$164M liquidity · $7M/mo burn
~20 mo
Low dilution risk
Lead asset
SutacimigPhase 2
Congenital Factor VII Deficiency →

Catalyst track record

+109%
best trade around COAG's most recent catalyst

Peak hindsight return over a 120-day window, across 3 tracked FDA/PDUFA catalysts for COAG.

See every catalyst's timing & PoA →